Go to
JCI Insight
Citations to this article
S Gupta, … , J Kim, S Gollapudi
Published April 1, 1991
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Abstract
Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.
Authors
S Gupta, J Kim, S Gollapudi
Total citations by year
Citation information
Citations to this article in year 2009 (1)
| Title and authors | Publication | Year |
|---|---|---|
|
Cytochrome P450-mediated metabolism in the human gut wall
K Thelen, JB Dressman |
Journal of Pharmacy and Pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)